Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has scheduled one-to-one meetings with investors and analysts on September 1-2, 2026, in Mumbai and virtually. No unpublished price-sensitive information will be shared during the meetings.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has scheduled one-to-one meetings with investors and analysts on September 1-2, 2026, in Mumbai and virtually. No unpublished price-sensitive information will be shared during the meetings.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has announced that certain equity share certificates have been transferred to the Investor Education and Protection Fund (IEPF) Authority due to being reported lost or misplaced. The company has published a notice in newspapers to inform shareholders about the transfer and to claim duplicate share certificates.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has appointed Mr. Chirag Shukla as its Company Secretary and Compliance Officer, effective August 20, 2026, as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has announced the opening of a special window for transfer and dematerialization of physical securities, allowing shareholders to transfer and dematerialize their physical securities which were sold/purchased prior to 1st April, 2019.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has announced the resignation of Ms. Manisha Saraf as Company Secretary & Compliance Officer, effective August 10, 2026.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd reported a strong Q1 FY27 with 26% YoY revenue growth, driven by growth across all major businesses, including a 7% growth in India branded business, 37% growth in International Generics, and 33% growth in API business. The company's external environment remains competitive with pricing pressure, regulatory expectations, and geopolitical uncertainties.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has announced the voting results of its 16th Annual General Meeting (AGM) held on August 5, 2026. The meeting was conducted through video conferencing, and the voting results show that all resolutions were passed with significant majority. The company also declared a dividend on equity shares for the financial year 2025-26.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd held its 16th Annual General Meeting on 5th August, 2026, through video conferencing, where the company's audited financial statements for the year ended 31st March, 2026, were adopted, and a dividend on equity shares for the financial year 2025-26 was declared. The meeting also approved the appointment of a new independent director and ratified the remuneration to the cost auditors for the financial year 2026-27.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended 30th June, 2026, with a total income from operations of ₹2,149.77 crores and a net profit of ₹221.86 crores.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has submitted the audio recording of its post-results conference call on August 4, 2026, which can be accessed on the company's website.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd reported its consolidated financial results for the first quarter ended 30th June 2026, with revenue from operations increasing by 26% YoY to Rs.2150 Cr, and EBITDA pre R&D increasing to Rs. 523 Cr; margin stood at 24%. The company's performance was driven by healthy volume growth, successful new product launches and continued execution across key markets.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter and year ended 30th June 2026, with revenue from operations increasing by 26% YoY to Rs.2150 Cr. Profit After Tax at Rs. 173 Cr, up 12% YoY, and EBITDA pre R&D increased to Rs. 523 Cr; margin stood at 24%. The company reported robust growth in India Branded Business, US Formulation, and API Business.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd announced its unaudited financial results for Q1 FY27, with revenue increasing by 26% YoY to INR 21.50 Bn, driven by 49% YoY growth in US Formulation and 33% YoY growth in API. EBITDA margin improved to ~24%, with a 7% YoY growth in EBITDA before R&D. The company reported a 33% YoY growth in PAT to INR 1.73 Bn, supported by a strong order book.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with a net profit of Rs. 173.07 crores and earnings per share of Rs. 8.80.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has announced its unaudited financial results for the quarter ended 30th June, 2026, with a revenue from operations of Rs. 2,149.77 crores and a profit for the period of Rs. 173.07 crores.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has received USFDA final approval for Prucalopride Tablets, 1 mg and 2 mg, a treatment for chronic idiopathic constipation in adults, with an estimated market size of $100 million.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has announced a conference call to discuss its Q1 FY27 unaudited financial results on August 4, 2026. The call will be held at 5:30 P.M. IST and can be accessed through a registration link or by dialing into a conference line.

Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 to consider and approve Unaudited Financial Results for the quarter ended 30th June, 2026.